{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-035107","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.639717+00:00","generated_at":"2026-06-07T09:05:37.618623+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pieris terminates German lease; pays €9.7M to exit ~$22M remaining obligations","bullets":["Lease termination effective Dec 31, 2023; fee of ~€9.7M paid to landlord.","Remaining lease payments totaled ~$18.4M, plus ~$3.9M for expansion through 2036.","Pieris vacates 105,000 sq ft lab/office in Hallbergmoos, retains equipment.","Limited use of property permitted until June 30, 2024 at no extra cost.","Part of strategic cost-reduction plan; security deposit to be returned."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-035107","json":"https://secwatch.observer/filing/0001437749-23-035107.json","markdown":"https://secwatch.observer/filing/0001437749-23-035107.md","text":"https://secwatch.observer/filing/0001437749-23-035107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923035107/0001437749-23-035107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923035107/pirs20231107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:05:37.618623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c693e615f987ec01c6d1cb7f0929e596cb5aff6e","claim":"PALVELLA THERAPEUTICS, INC. terminated Lease Termination Agreement with Hallbergmoos Grundvermögen GmbH valued at termination fee of approximately €9.7 million; remaining lease payments of approximately $18.4 milli (effective 2023-12-15).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, Pieris Pharmaceuticals GmbH (\"Pieris GmbH\"), a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the \"Company\"), entered into a lease agreement with Hallbergmoos Grundvermögen GmbH (\"Lessor\") on October 24, 2018, which was subsequently amended on May 21, 2019, February 13, 2020 and May 19, 2020 (collectively, the \"Lease Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923035107/0001437749-23-035107-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"Hallbergmoos Grundvermögen GmbH"},{"label":"Value","value":"termination fee of approximately €9.7 million; remaining lease payments of approximately $18.4 milli"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}